SRTA · Strata Critical Medical, Inc.
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Aug 4, 2026TL;DR. Strata posted Q2 revenue up 60.7% to $72.5M with strong clinical growth, closed three bolt-on acquisitions, and raised 2026 revenue guidance to $285–295M and adjusted EBITDA to $33–35M, while logistics growth and margin softened due to a one-customer volume reduction.
- + Closed three bolt-on acquisitions adding ~$20M revenue and $6.3M projected annualized adjusted EBITDA
- + Adjusted EBITDA margin expanded 140 bps sequentially to 10.9% with $7.9M adjusted EBITDA
- − Logistics gross margin fell to 18.4% from 19.3% sequentially and below ~20% expectation; guided to only 18.5–20% for H2
- − Logistics revenue headwind of ~3% from a non-exclusive customer reducing flying for one organ type
- − Q3 logistics revenue expected to decline high single digits sequentially due to customer reduction and summer seasonality
- − Logistics gross profit declined 1.3% YoY to $8.9M with gross margin down 160 bps to 18.4%
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Medical Care Facilities — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SRTA
this stock
Strata Critical Medical, Inc.
|
$471.53M | +0.4% | +34.3% | 10.7 | 4.9% |
|
HCA
HCA Healthcare, Inc.
|
$96.64B | -9.3% | +7.1% | 15.0 | 2.9% |
|
FSNUY
Fresenius SE & Co. KGaA
|
$29.92B | -13.1% | — | — | 0.0% |
|
THC
Tenet Healthcare Corp
|
$20.91B | +27.8% | +0.9% | 10.0 | 2.5% |
|
EHC
Encompass Health Corp
|
$12.18B | +12.2% | +10.5% | 20.1 | 3.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SRTA | -8.4% | -10.4% | +19.6% | -5.5% | +0.4% |
| SPY | -0.4% | -0.2% | +12.4% | +0.2% | +12.0% |
| vs SPY | -7.9% | -10.2% | +7.1% | -5.7% | -11.6% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.